Xencor, Inc. $XNCR Shares Purchased by Baker BROS. Advisors LP

Baker BROS. Advisors LP increased its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 64.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,102,106 shares of the biopharmaceutical company’s stock after acquiring an additional 431,675 shares during the quarter. Baker BROS. Advisors LP owned approximately 1.54% of Xencor worth $12,928,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Walleye Capital LLC acquired a new stake in shares of Xencor during the 2nd quarter worth approximately $1,955,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Xencor by 153.2% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 29,371 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 17,773 shares during the period. Squarepoint Ops LLC boosted its position in Xencor by 3,150.0% during the 2nd quarter. Squarepoint Ops LLC now owns 363,153 shares of the biopharmaceutical company’s stock valued at $2,854,000 after purchasing an additional 351,979 shares during the period. SG Americas Securities LLC bought a new position in Xencor during the 3rd quarter worth $1,062,000. Finally, Primecap Management Co. CA grew its stake in Xencor by 1.4% during the 3rd quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock worth $125,218,000 after buying an additional 147,700 shares during the last quarter.

Wall Street Analyst Weigh In

XNCR has been the topic of a number of recent research reports. Wall Street Zen cut Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Barclays upped their price target on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a report on Monday, December 29th. Finally, Truist Financial started coverage on shares of Xencor in a research report on Monday, November 24th. They issued a “buy” rating and a $29.00 price objective on the stock. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

Xencor Stock Up 3.4%

Shares of Xencor stock opened at $12.00 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.25 and a quick ratio of 6.25. Xencor, Inc. has a 1-year low of $6.92 and a 1-year high of $18.69. The business’s fifty day moving average price is $12.47 and its two-hundred day moving average price is $13.10. The company has a market capitalization of $880.08 million, a P/E ratio of -9.68 and a beta of 0.95.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.55. The company had revenue of $28.24 million during the quarter, compared to analysts’ expectations of $29.97 million. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The company’s revenue for the quarter was down 46.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.62) earnings per share. As a group, research analysts forecast that Xencor, Inc. will post -3.68 EPS for the current year.

Insider Activity at Xencor

In other Xencor news, SVP Celia Eckert sold 3,244 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $36,495.00. Following the transaction, the senior vice president owned 78,685 shares of the company’s stock, valued at approximately $885,206.25. This trade represents a 3.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP John R. Desjarlais sold 73,367 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the sale, the vice president owned 236,574 shares in the company, valued at $3,718,943.28. This trade represents a 23.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 231,764 shares of company stock worth $3,450,009 in the last 90 days. Corporate insiders own 4.76% of the company’s stock.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.